Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa


Jacob Bor and colleagues use demographic data from a longitudinal surveillance cohort to identify increased gains in life expectancy among women compared to men in the years following antiretroviral therapy scale-up in rural South Africa.


Published in the journal: . PLoS Med 12(11): e32767. doi:10.1371/journal.pmed.1001905
Category: Research Article
doi: 10.1371/journal.pmed.1001905

Summary

Jacob Bor and colleagues use demographic data from a longitudinal surveillance cohort to identify increased gains in life expectancy among women compared to men in the years following antiretroviral therapy scale-up in rural South Africa.

Introduction

The scale-up of HIV antiretroviral therapy (ART) in HIV-endemic settings has led to large gains in adult life expectancy at the population level [1,2]. Yet in many parts of southern Africa, HIV remains the leading cause of death [3]. Since 2004, South Africa has provided ART at no charge to patients in public sector clinics and hospitals, and over 2 million South Africans are currently receiving therapy [4].

This paper investigates the differential impact of mass HIV treatment on survival of men and women in the general population. We assess sex-specific trends in adult life expectancy and HIV-related mortality. To shed light on why men and women continue to die from HIV when ART is widely available, we investigate where in the cascade of care HIV mortality occurs, how these patterns differ by sex, and how they have changed over time with ART scale-up.

Globally, female life expectancy is about 4.7 y longer than male life expectancy (70.9 versus 66.2 y) [5], yet this life expectancy gap varies across space and time. Female–male differences in life expectancy are the product of biological, behavioral, and environmental factors, including sex-specific patterns in exposure to disease risks and access to treatments. During the 1990s and early 2000s, epidemic HIV/AIDS compressed the female–male life expectancy gap in many of the hardest hit countries in sub-Saharan Africa (S1 Fig) [5]. Little is known about how the expansion of HIV treatment has affected disparities in sex-specific survival.

Differential trends in life expectancy for men and women with ART scale-up may reflect both differences in the underlying burden of HIV disease and differences in access to HIV care and treatment services. Previous studies in southern Africa have documented sex differences in rates of progression at specific stages in the HIV cascade of care. Women have higher rates of HIV testing [6] and linkage to care [79] than men. Among patients not yet eligible for ART, women are more likely to be retained in pre-ART care [10]. Men tend to initiate ART at lower CD4 counts and in worse health [1113]. And there is evidence that men have worse adherence [14] and lower retention on therapy [12] once initiated on ART. Sex differences have also been widely reported in health outcomes among patients who have initiated ART, with male patients experiencing higher mortality [12,1517] and worse recovery of immune function [17].

The cumulative impact of these relative disadvantages for men and how they have evolved over time has not been described. We assess changes in survival among men and women ≥15 y in the general population in an entire community under continuous demographic and health surveillance before and during the rapid scale-up of ART. This community is characterized by very high HIV prevalence [18] and high ART coverage [1,19]. By taking a population-based perspective, we capture the full cascade of HIV care and treatment, including persons who have not yet accessed the medical system. This is critically important given the high proportion of HIV-infected South Africans who are not aware that they are HIV-positive (62% of males and 45% of females in 2012) [6] and who nevertheless may be at risk for death due to HIV. Facility-based studies do not observe this important population, and cross-sectional HIV surveillance studies do not measure mortality. The analysis presented here highlights opportunities for future interventions to reduce the lingering burden of HIV mortality in the context of nominally free and widely available treatment.

Methods

Ethics

Ethical approval for data collection, linkage, and analysis by the Africa Centre for Population Health (Africa Centre) was obtained from the University of KwaZulu-Natal Biomedical Research Ethics Committee. Verbal informed consent was obtained from household respondents. The analyses conducted for this paper consisted of secondary analysis of de-identified data.

Data

The Africa Centre is one of the Wellcome Trust's five major overseas programs. As one of its core activities, the Africa Centre operates a large health and demographic surveillance site in rural KwaZulu-Natal, South Africa. All members of all households located in a 438-km2 demographic surveillance area (DSA) are followed up longitudinally on a range of demographic, health, and socioeconomic indicators through regular household surveys. The area has an adult HIV prevalence of 29% [18], and just 34% of working age adults are employed [20]. Since 2000, the Africa Centre has conducted demographic surveillance through semi-annual household visits. Over 150,000 individuals in more than 20,000 households have been included in the surveillance; household response rates exceed 99% [21]. The surveillance population includes all members of all households—including household members who are not currently residing in the surveillance area (non-resident household members), which is an important feature given high rates of migration in rural South Africa. Following every death in the surveillance area that is recorded by the surveillance teams, the household of the deceased is visited by a trained nurse who conducts a verbal autopsy interview to determine the probable cause of death. Data on the events leading up to the death are recorded in a standardized form; these data are fed into a computerized algorithm (InterVA), and a cause of death is probabilistically assigned [22,23]. Response rates in the verbal autopsy data are very high. During the period 2001–2011, 93.0% of all deaths had a cause of death assigned by verbal autopsy, 5.3% were missing/refused, and 1.7% were indeterminate.

In addition to the demographic surveillance, the Africa Centre maintains a clinical database for all patients in the public sector HIV and Treatment program (Hlabisa HIV Treatment and Care Programme) that has served the DSA since the national HIV treatment program began in 2004. Clinical records have been linked at the individual level with the demographic surveillance using national identification numbers, full name, age, and sex, enabling assessment of the demographic implications of public sector treatment scale-up [19,20]. Private sector utilization for ART is low in the community due to the high cost of ART outside the public sector and low levels of private insurance coverage.

For this analysis, dates of birth, death, and residency episodes were obtained for the complete population under surveillance from 1 January 2001 through 31 December 2011. Deaths were coded as HIV-related or not HIV-related based on the verbal autopsy interviews. Since tuberculosis (TB) is a common opportunistic infection and common immediate cause of death for people with HIV in this community, TB-related deaths were coded as HIV-related, consistent with previous analyses of these data [1,22,24,25]. The use of verbal autopsy to identify HIV-related deaths has important advantages over approaches using HIV biomarker surveillance, an alternate approach in the literature [2]. First, deaths occurring in HIV-infected persons but due to other causes (e.g., vehicle accidents, non-communicable diseases) are not attributed to HIV. Second, our approach is not vulnerable to the high rates of non-response in HIV biomarker surveillance, which is likely to be correlated with true HIV status [26].

Into the Africa Centre’s demographic database were merged clinical data from the public sector HIV care and treatment program: date of first recorded CD4 count—a proxy for the date of entry into clinical HIV care—and date of ART initiation. We divided person-time into four mutually exclusive, collectively exhaustive categories: (1) never sought care (no CD4 count); (2) sought care (CD4 count) but never initiated ART; (3) initiated ART within the previous year; (4) initiated ART more than 1 y ago. We distinguish between the first and later years on ART due to widely documented higher mortality in the first year on therapy [27].

Study Population and Inclusion Criteria

The study population included all resident and non-resident adult (≥15 y old) members of all households under surveillance, 2001–2011. Dates and causes of death were ascertained through household proxy for all members of the study population—regardless of whether they resided in the surveillance area. Person-time was included from the date an individual was first observed in the surveillance or their 15th birthday until the date that person exited the surveillance, through death or because they ceased to be a member of a household under surveillance. For analyses that disaggregated individuals by whether they had sought care or initiated ART, we limited the study population to persons residing in the DSA for at least 90 days, because non-resident household members would have been more likely to seek HIV care and treatment outside the Hlabisa catchment area.

Data Analysis

Sex-specific trends in adult life expectancy

Life expectancy is a summary metric of the mortality experience in a population and is widely used to compare mortality across populations and over time. Life expectancy is an expectation in the statistical sense: it is the mean number of years a cohort would live if it were exposed to the full profile of age-specific all-cause mortality rates observed in a population in a given period of time. Life expectancy is a period measure and may differ from the average length of life for members of a birth cohort, which is only observed after all members have died. For example, if age-specific mortality rates declined with calendar time, then life expectancy would underestimate the average length of life for a birth cohort.

Adult life expectancy is the number of additional years of life expected, conditional on survival to age 15 y, and is commonly denoted e15. We calculated e15 separately for men and women using a continuous-time approach[1]: for each calendar year in 2001–2011, we estimated sex-specific survival curves beginning at age 15 y, using the non-parametric Kaplan-Meier estimator. To obtain annual sex-specific estimates of e15, we numerically integrated under the annual sex-specific survival curves. Due to sparseness of data beyond age 95 y, we censored the annual survival curves at age 95 y and calculated the expected number of years lived in the 80-y interval between ages 15 and 95 y (80e15). A correction factor equal to life expectancy at age 95 y (e95) was estimated separately for each sex for the entire period 2001–2011 and was added to our annual estimates of 80e15 to obtain annual estimates of e15. Throughout this paper, we report adult life expectancy as e15 + 15 y, so that estimates correspond to ages at death rather than years remaining at age 15 y [1]. To quantify the evolution of sex disparities in adult life expectancy, we calculated the female-to-male gap in adult life expectancy in each calendar year for 2001–2011, sex-specific changes in adult life expectancy between 2003—prior to the beginning of ART scale-up—and 2011, and the difference in sex-specific changes in adult life expectancy from 2003 to 2011. We bootstrapped at the individual level (101 resamples) to estimate standard errors and constructed 95% percent confidence intervals for each of these comparisons.

To assess the contribution of HIV-related mortality to trends in adult life expectancy, we next estimated HIV-cause-deleted adult life expectancy, separately for men and women. HIV-cause-deleted adult life expectancy was estimated using the approach described above, except that HIV-related deaths identified in verbal autopsy were coded as censored on the date of death rather than included as deaths. Mechanistically, trends in HIV-cause-deleted life expectancy show changes in the rate and age distribution of mortality due to all other causes. Under the assumption that mortality due to HIV and mortality due to other causes are independent, HIV-cause-deleted life expectancy reflects the life expectancy that would exist if HIV-related mortality were eliminated. Under this assumption, the difference between HIV-cause-deleted adult life expectancy and adult life expectancy would reflect the years of life lost due to HIV. Although the independence assumption cannot be tested directly, it is consistent with prior evidence that HIV-infected persons on ART in sub-Saharan Africa have life expectancies close to those in the general population [27,28]. Sensitivity analyses assessing the robustness of our HIV-cause-deleted life expectancy estimates to deviations from the independence assumption—as well as further discussion of this assumption—are presented in S1 Text.

Sex-specific trends in HIV-related mortality

We assessed trends in HIV-specific mortality rates by sex and estimated trends in female-to-male HIV mortality rate ratios. If ART scale-up had the same proportional effect on HIV mortality for men and women, then the ratio of HIV mortality for women to HIV mortality for men would be expected to be constant over time. We estimated female-to-male HIV mortality rate ratios for each calendar year in 2001–2011 using an exponential hazard model, in which time to HIV death was regressed on indicators for each calendar year and the interaction of those indicators with sex. To test whether the relative change in HIV mortality over time differed for men and women, we estimated a similar hazard model but included a main effect for female, set calendar year = 2003 as the reference category, and made inferences on the interaction between female and calendar year = 2011. To control for potential confounding by age, we additionally controlled for age group indicators (15–29, 30–44, 45–64, 65+ y) in an age-adjusted hazard model. Finally, we stratified the analysis by age. We regressed time to HIV death on indicators for year-by-age strata and indicators for sex-by-year-by-age strata. Annual age-specific female-to-male HIV mortality rate ratios were obtained by exponentiating the coefficients on the latter terms, and we tested the null hypothesis that the relative changes in HIV mortality for women versus men over the period 2003–2011 were constant across age groups. In all models, person-time was censored at exit from the surveillance, either because a person ceased to be a member of a household under surveillance or because he or she died from another cause. To adjust for non-independence of the person-time contributed by the same individuals in different years, we clustered standard errors at the individual level in all regression analyses.

Sex-specific differences in progression through the HIV cascade of care and attribution of HIV-related deaths across the cascade

Differences in HIV mortality trends may be due to differences in access to HIV care and treatment. To assess sex differences in progression through the HIV cascade of care, we calculated the proportion of all surviving adults (ages 15 y and over) in the population residing in the DSA who (1) had ever sought care in the public sector ART program, as evidenced by a recorded CD4 count, or (2) had ever initiated ART in the public sector ART program. Proportions were assessed annually for 2001–2011 at mid-year (July 1), and exact 95% CIs estimated.

We disaggregated HIV-related deaths into four groups defined by whether the deceased had ever sought care and/or initiated ART in the public sector ART program: (1) never sought care. (2) sought care but never initiated ART, (3) initiated ART less than 1 y prior to death, or (4) initiated ART more than 1 y prior to death. This analysis was limited to persons who were at least 15 y old on their date of death. We also excluded persons who migrated into the DSA in the 90 d before their date of death, in order to exclude people who died from HIV but might not have had the opportunity to seek care for HIV in the local public sector ART program [29]. For each calendar year from 2001 to 2011, the distribution of deaths across these four care-seeking categories was evaluated separately for men and women. Lastly, HIV mortality rates were calculated for the population residing in the DSA on 1 January 2011, by care-seeking category. Female-to-male HIV mortality rate ratios were estimated separately for each stage in exponential hazard models adjusting for age (15–29, 30–44, 45–64, 65+ y). In alternate specifications, we additionally controlled for log(CD4 count at entry into care + 1) for stage 2 above and for log(last CD4 count before ART initiation + 1) for stages 3 and 4 above. Person-time was censored at exit from the surveillance, death due to a competing cause, or the date of transition to the next stage in the cascade of care.

The validity of our attribution of HIV-related deaths across the cascade of care depends on the accuracy of verbal autopsy coding. Persons who died from other causes but whose death was attributed to HIV might not have even been HIV positive and would have been less likely to have sought care for HIV since they would have had no reason to do so. In robustness checks, we limited the sample of deaths to those that specifically named HIV as a cause, those that named HIV as a cause with an InterVA likelihood score > 90%, those that named either HIV or TB as a cause, and those that named either HIV or TB as a cause with an InterVA likelihood score > 90%. For further information, see S2 and S3 Texts.

Results

All adult person-time contributed by members of the demographic surveillance from 2001 through 2011 was analyzed. In all, 52,964 women and 45,688 men contributed a total of 615,075 person-years to the analysis (Table 1). Attrition from the population surveillance was comparable for men and women, at 3.0 and 3.3 per 100 person-years, respectively. A total of 12,290 deaths were reported during follow-up, of which 7,229 (58.8%) were identified by verbal autopsy to be HIV/TB-related.

Tab. 1. Population demographic surveillance 2001–2011: summary statistics.
Population demographic surveillance 2001–2011: summary statistics.
Study population includes all members of all households in the DSA over age 15 y. Individuals come under observation when they turn 15 y old or when they join a household under surveillance. Individuals exit observation when they cease to be members of a household under surveillance. Non-resident household members were included in the assessment of mortality trends but were excluded from the analysis decomposing HIV deaths across the cascade of care. PY, person-years.

Sex-specific trends in adult life expectancy are presented in Fig 1. For both men and women, adult life expectancy fell in the early 2000s and then began to rise after ART scale-up began in 2004. Women experienced substantially larger gains in survival than men, however. For women, adult life expectancy increased from 51.3 y (95% CI 49.7, 52.8) in 2003 to 64.5 y (95% CI 62.7, 66.4) in 2011, a gain of 13.2 y 95% CI 10.7, 15.8). For men, adult life expectancy increased from 46.9 y (95% CI 45.6, 48.2) in 2003 to 55.9 y (95% CI 54.3, 57.5) in 2011, a gain of 9.0 y (95% CI 6.9, 11.1). Over this period, the female–male gap in adult life expectancy nearly doubled, from 4.4 y in 2003 (95% CI 2.3, 6.5) to 8.6 y in 2011 (95% CI 6.1, 11.1) (Fig 2), a statistically significant difference of 4.3 y (95% CI 0.9, 7.6).

Adult life expectancy and HIV-cause-deleted adult life expectancy, 2001–2011, by sex.
Fig. 1. Adult life expectancy and HIV-cause-deleted adult life expectancy, 2001–2011, by sex.
Solid symbols are annual estimates of adult life expectancy; open symbols are annual estimates of HIV-cause-deleted adult life expectancy. 95% CIs are shown. The black dashed line indicates the beginning of ART scale-up in 2004.

Female–male difference in adult life expectancy, 2001–2011.
Fig. 2. Female–male difference in adult life expectancy, 2001–2011.
Solid blue circles display annual estimates of the gap between female and male adult life expectancy. The red dashed line indicates the gap in HIV-cause-deleted life expectancy observed in 2011. The black dashed line indicates the beginning of ART scale-up in 2004.

During the period 2001–2011, HIV-cause-deleted life expectancy remained approximately stable in both men and women (Fig 1), indicating that the changes in adult life expectancy were indeed driven by changes in HIV-related mortality. As Fig 1 shows, however, HIV-cause-deleted life expectancy is much higher for women than for men at about 75 and 65 y, respectively, largely because of the high burden of mortality from injury for young men in this setting [30]. Because of lower competing mortality risks, women have larger potential gains in years of life from ART scale-up; in other words, the benefits of avoiding HIV mortality are greater for women than for men. The “potential gains” in survival can be seen in the outermost curves in Fig 3, which compares sex-specific survival curves for 2003, 2011, and HIV-cause-deleted survival. (S1 Table presents the risk table corresponding to Fig 3.) However, as shown in Fig 3, not only do women have longer potential life expectancy: by 2011, women were also relatively closer than men to recovering the HIV-cause-deleted estimate of their potential life expectancy, vis-à-vis the 2003 nadir in life expectancy prior to the public sector scale-up of ART. Interpreting HIV-cause-deleted life expectancy as the potential life expectancy that could be achieved in the absence of HIV-related mortality depends on the assumption that HIV and other causes of death are independent. In sensitivity analyses, in which we computed alternate estimates of HIV-cause-deleted adult life expectancy assuming very strong positive (or negative) dependence between HIV and other causes of death, our results were not substantially changed (S1 Text).

Sex-specific survival curves: 2003, 2011, and HIV-cause-deleted.
Fig. 3. Sex-specific survival curves: 2003, 2011, and HIV-cause-deleted.
Sex-specific continuous-time Kaplan-Meier survival curves for 2003 and 2011 are shown. The HIV-cause-deleted survival curves pool person-time for 2001–2011. These are period (synthetic cohort) survival curves reflecting age-specific mortality rates in a population in a given period of time; life expectancy is calculated as the area under the curve. A risk table showing persons at risk and deaths at each age for each of the six survival curves is available as S1 Table.

Table 2 presents population HIV mortality rates for men and women for each calendar year in 2001–2011, as well as female-to-male HIV mortality rate ratios. HIV mortality declined in both men and women, but declined faster for women. Among women, HIV mortality declined from 1.60 deaths per 100 person-years (95% CI 1.46, 1.75) in 2003 to 0.56 per 100 person-years (95% CI 0.48, 0.65) in 2011. For men, HIV-related mortality declined from 1.71 per 100 person-years (95% CI 1.55, 1.88) to 0.76 per 100 person-years (95% CI 0.67, 0.87) over the same period. Whereas women were no less likely than men to die from HIV in 2003 (rate ratio [RR] = 0.93; 95% CI 0.82, 1.07), by 2011 women were 27% less likely to die from HIV than men (RR = 0.73; 95% CI 0.60, 0.89). The decline in the relative rate of HIV death for women vis-à-vis men from 2003 to 2011 was statistically significant in both the crude (RR = 0.78; 95% CI 0.61, 1.00; p = 0.046) and age-adjusted analysis (RR = 0.77; 95% CI 0.61, 0.98; p = 0.036) (S2 Table).

Tab. 2. HIV mortality rates for females and males, 2001–2011.
HIV mortality rates for females and males, 2001–2011.
PY/100 = person-years divided by 100. The table includes all adult (15+ y) members of households in the demographic surveillance. Female-to-male rate ratios were estimated in an exponential hazard regression model in which time to HIV-related death was regressed on calendar year and the interaction between calendar year and female.

Due to differences in age-specific HIV mortality rates for men and women, there is substantial cross-sectional heterogeneity in age-specific female-to-male HIV mortality rate ratios. Women have relatively higher HIV mortality at younger ages; men have higher HIV mortality at older ages. Though we were underpowered to detect age-specific changes, the female-to-male HIV mortality rate ratio appeared to decline in most age groups (Fig 4; S3 Table), and we could not reject the hypothesis of a constant effect across age groups. Female sex has emerged as a protective risk factor for HIV mortality as HIV treatment has become more widely available.

Female-to-male HIV mortality rate ratios by age and calendar year, 2001–2011.
Fig. 4. Female-to-male HIV mortality rate ratios by age and calendar year, 2001–2011.
Age-specific HIV mortality rate ratios for women versus men were estimated in an exponential hazard regression model that included calendar year indicators for each age group and interactions for each age and year with sex. The 45–64 y and 65+ y age groups were combined to improve precision at older ages. The pooled estimate is from a separate regression model. Mortality rate ratios declined after 2004 in all age groups.

Although men and women had similar rates of HIV mortality at the population level before the ART scale-up, men and women have had starkly different levels of utilization of HIV care and treatment since then. In 2011, 9.0% (95% CI 8.6%, 9.4%) of all women in the population had initiated ART, and an additional 7.9% (95% CI 7.6%, 8.3%) had sought care and had a CD4 count recorded but had not yet initiated ART. Yet just 4.2% (95% CI 3.9%, 4.6%) of all men had initiated ART, and only an additional 2.4% (95% CI 2.1%, 2.6%) of men had sought care but not yet initiated ART (S2 Fig). Over twice as many women had accessed care or initiated ART as men: 16.9% versus 6.6%.

To provide insight into some of the reasons behind these growing female–male disparities, we decomposed deaths due to HIV across different stages in the cascade of care (Figs 5 and S3). In spite of widespread access to ART free of charge at all local clinics, a large proportion of deaths due to HIV occurred among persons who had never sought care for HIV in the public sector treatment program. This phenomenon was particularly pronounced among men. In 2011, 39.8% (95% CI 31.0%, 48.7%) of female HIV-related deaths and 55.1% (95% CI 46.1%, 64.1%) of male HIV-related deaths were among persons who had never sought care (p-value for difference in proportions = 0.019). Conditional on seeking care, the distributions of deaths across the other categories—sought care but did not initiate ART (28.2% versus 28.3%), initiated ART less than 1 y ago (35.2% versus 34.0%), initiated ART more than 1 y ago (36.6% versus 37.7%)—were similar for men and women. The proportion of deaths among those who never sought care declined substantially over time for both men and women as access to HIV care and treatment expanded (Fig 5; S4 Table). These results were robust to different definitions of an HIV-related death as diagnosed by verbal autopsy. Restricting the sample to those deaths that were >90% likely to be HIV-related according to the InterVA diagnostic algorithm yielded proportions of 42% and 62% for the percent of HIV deaths occurring in women and men who had never sought care for HIV (S5 Table).

Distribution of HIV deaths across cascade of care, 2001–2011.
Fig. 5. Distribution of HIV deaths across cascade of care, 2001–2011.
We excluded all deaths that occurred within 3 mo of migrating into the DSA, as the deceased may not have had the opportunity to seek HIV care in the local health system.

HIV mortality rates were substantially higher for men than for women at each stage of the cascade (Table 3). Among persons who initiated ART at least 1 y prior, HIV mortality was 1.31 per 100 person-years for women and 2.88 per 100 person-years for men in 2011. Rates were 3.37 and 8.49 deaths per 100 person-years for women and men, respectively, in their first year of ART, and 0.76 and 2.45 deaths per 100 person-years for women and men in pre-ART care. Although HIV mortality rates were lowest among persons who had not sought care for HIV—0.21 for women and 0.34 for men—this group represented 83% of women and 93% of men in the population, and hence contributed the largest number of HIV deaths at the population level, as shown in Table 3 and Fig 5.

Tab. 3. HIV mortality across the cascade of care in 2011 (ages 15+).
HIV mortality across the cascade of care in 2011 (ages 15+).
HIV mortality rates were calculated for men and women who were residing in the DSA and at least 15 y on 1 January 2011. Care-seeking category was defined on 1 January 2011; observations were censored on the date when individuals changed care stage. The group “never sought care” includes persons who were not (yet) infected with HIV. Relative rates were computed in an exponential hazard model adjusting for the age categories 15–29, 30–44, 45–64, and 65+ y. Pre-ART CD4-adjusted models were adjusted for log(earliest CD4 count); ART 0–1 y and ART >1 y CD4-adjusted models were adjusted for log(last CD4 count before ART initiation). The female-to-male HIV mortality rate ratio reported here is lower than that reported in Table 2 because sex disparities in HIV mortality were larger for DSA residents compared with non-resident members of the surveillance; non-residents were excluded in the analyses presented in this table.

Discussion

Mass provision of free ART in public sector facilities in South Africa has coincided with dramatic reductions in HIV-related mortality for both men and women. However, the decline in HIV mortality for women has substantially outpaced the decline for men. Prior to ART scale-up, epidemic HIV had substantially compressed the female–male gap in adult life expectancy because of women’s younger average age at infection and longer lifespan in the absence of HIV. Access to life-prolonging treatment has led not only to the natural decompression of the female–male adult life expectancy gap but also to the unanticipated emergence of male sex as a significant predictive risk factor for HIV mortality at the population level in this setting. Since the start of the ART scale-up in 2004, the female–male gap in adult life expectancy has nearly doubled.

Is the emergent male disadvantage in HIV mortality a fleeting pattern, a blip on the road to universal treatment coverage? Or are we on the path to sustained sex disparities in HIV mortality? To better understand the lingering mortality burden due to HIV, a critical question is where in the HIV cascade of care HIV-related deaths are occurring. By linking data on dates and causes of death from a large population surveillance system with clinical records from South Africa’s national ART program, we decomposed the distribution of HIV deaths in this population across the cascade of care and assessed differences by sex. In spite of the widespread availability of ART, about half of all HIV-related deaths in 2011 occurred among persons who had never sought care in the public sector HIV care and treatment program (55% for men; 40% for women). While previous studies have documented excess mortality among male ART patients [12] and among men receiving pre-ART care [10], this study is the first, to our knowledge, to document the relative significance of HIV mortality among persons who have never sought care and substantial excess mortality among men in this difficult-to-access population.

There are a number of possible explanations for the growing disparity in HIV mortality between men and women. Social norms regarding care-seeking and disclosure of HIV status may present significant barriers to access and adherence for men [31], similar to male care-seeking deficits observed in other settings and for other conditions [32]. Women may be more familiar with local clinics because of their utilization for maternal and child health care. The very successful national program to prevent mother-to-child transmission may encourage HIV-infected women to access and remain in HIV care [33]. In a previous analysis of this cohort, however, accessing care during pregnancy explained only a small fraction of the sex disparity in HIV treatment uptake [8]. Men may also face specific social and cultural barriers to participation in adherence-promoting activities like support groups [34]. Clinics are generally open only during working hours, and with higher employment rates among men than women in this setting [20], this may be a contributing factor. Additionally, high rates of long-distance labor migration may further complicate access to and retention in care for men [35].

We note that higher HIV mortality rates observed for men receiving HIV care and treatment may result from sex differences in adherence and retention behaviors as well as from differences between men and women in the composition of patients seeking care and initiating ART. In previous research on this cohort, we found that men were less likely than women to initiate ART when eligible [8] and that when men did initiate ART, they did so at lower CD4 counts [20]. Delayed care-seeking not only leads to excess mortality among men who have never sought care, but also likely contributes to the excess mortality among men observed at each subsequent stage in the cascade of care through its impact on the composition of patients at each stage. CD4 count at entry into each stage of the cascade offers a noisy, but useful, proxy for mortality risk. Although the male disadvantage in HIV mortality was somewhat attenuated after controlling for CD4 count, men were still twice as likely to die from HIV at each stage in the cascade.

We have documented that a substantial proportion of HIV-related deaths occur among people who have never sought care. Further research is needed to understand the reasons that people dying from HIV choose not to seek lifesaving treatment that is widely available and free of charge. Given the higher risk faced by men, population-wide interventions could be implemented to educate men about the benefits of timely ART initiation for one’s own health [36] and economic productivity [20,37,38], the economic well-being of the household [39,40], and the health of one’s sex partners [41]. Messages could be targeted to settings that men frequent, e.g., football pitches, workplaces, shabeens, and public taxis. Similarly, interventions could emphasize the normalization of ART through sensitization of men to the large number of men and women currently receiving therapy and the very large number of people (40% of the population) who live with someone who has either sought care for HIV or initiated ART [19]. At the same time, changes in public sector service delivery—e.g., by offering clinic hours on weekends rather than solely during working hours, or delivering antiretroviral drugs to non-clinic pick-up points, such as workplaces or local shops—might reduce the costs of care-seeking and encourage men to seek care[42]. Finally, we note the potential complementarity between interventions at different points in the cascade of care: interventions to reduce mortality and improve quality of life among male patients receiving ART may improve community perceptions of treatment and increase uptake of HIV testing, care, and treatment services [43].

Our study assessed trends in adult life expectancy and HIV-related mortality in an HIV-endemic setting in rural South Africa, in the context of South Africa’s national HIV treatment scale-up. The quality of the data is a major strength of this analysis. Data on dates of death were collected through semi-annual household surveys with >99% response rates [21]. Because the data come from population-based surveillance, we observe individuals regardless of whether they have ever sought clinical care and thus capture HIV mortality in individuals who never linked into care or initiated ART. The population perspective also means that we observe individuals and their survival regardless of whether they are retained in clinical care, a challenge in many clinical cohorts. Individuals even continue to be observed if they migrate out of the surveillance area, so long as they remain members of households under surveillance. Verbal autopsy data were collected by trained nurses for all deaths, with a 93% response rate, and HIV/TB-related deaths were identified using a validated algorithm [22]. Results were robust to different coding definitions of HIV-related deaths, as reported above. Dates of ART initiation and CD4 counts were obtained from complete clinical records for the public sector ART program that serves the surveillance area and were linked using individual identifiers [19].

Our study had some limitations. First, because of the nature of the data, we report on only one rural setting in one province in South Africa. We note, however, that this area is in one of the poorest districts in South Africa and has many features—high unemployment, high migration, complex household arrangements, low private sector utilization for HIV treatment—common to rural areas with high HIV prevalence in southern Africa. Second, we report on trends in adult life expectancy and HIV mortality before and during the scale-up of public sector HIV treatment in South Africa. Although the changes in mortality patterns observed coincided with the beginning of ART scale-up in 2004 and progressive expansion of services through 2011, we cannot rule out that other contemporaneous factors could have influenced population mortality trends, such as survivorship effects. In a previous analysis, we simulated the counterfactual path of the epidemic and demonstrated that no rapid increase in life expectancy was predicted based on the internal dynamics of the HIV epidemic in the absence of ART scale-up [1]. Additionally, HIV-cause-deleted adult life expectancy, a summary measure of non-HIV-related mortality, was relatively constant for both men and women across the study period. Third, our data on the cascade of HIV treatment services exclude patients seeking care in the private sector. Though a limitation, we note that private sector care-seeking for HIV treatment is rare in this setting, given the free provision of ART in the public sector. Fourth, we divided the treatment cascade into four discrete, easily defined stages: never had a CD4 count recorded, had a CD4 count recorded but never initiated ART, initiated ART less than a year ago, and initiated ART more than a year ago. These definitions may be conservative: persons who sought care or initiated ART may not still be in care. Investigating sex-specific patterns of clinical attrition and churning, and their contribution to survival disparities between men and women on ART, is an important topic for future research.

As with all verbal autopsy approaches, our method of identifying HIV-related deaths may have resulted in some misclassification. The quality of verbal autopsy data depends on the skill of the interviewer, the willingness of household members to participate, the accuracy of their recall, and the validity of the algorithm used to make diagnoses based on reported symptoms. The underlying data for verbal autopsy at Africa Centre come from high-frequency (twice- and later thrice-annual) demographic surveillance, with autopsy interviews conducted by trained nurses on average 6 mo following a recorded death; in contrast, other surveys have used lay health workers or field interview staff to conduct verbal autopsies and/or relied on longer recall intervals following a death [24,25]. Response rates were very high, with 93% of all deaths assigned a cause of death by verbal autopsy. An active literature has sought to develop and validate verbal autopsy classification algorithms [22,25,44,45]. We used an algorithm (InterVA) that is widely used and has been shown to have high validity in identifying HIV/TB-related deaths in populations with high HIV prevalence [22,24,25]. In particular, the algorithm has been validated locally against physician-coded verbal autopsies in the Africa Centre’s demographic surveillance [22]. TB is a common opportunistic infection in HIV-infected persons, and it can be difficult to distinguish a TB-related death from an HIV-related death. Following previous studies [1,22,25], we coded all TB-related deaths as HIV-related. We note as a limitation that the inclusion of TB-related deaths may somewhat overstate the total number of HIV-related deaths, but this effect is likely to be small: a prior analysis of the Africa Centre surveillance calculated that out of the 53.5% of all adult deaths due to HIV or TB, just 5.3% were attributable to TB without HIV [46]. Further, the inclusion of TB-related mortality is appropriate given the potential spillover effect that ART scale-up may have in reducing the population burden of active TB and transmission of TB to HIV-uninfected persons [47]. Our results were robust to a variety of alternate codings of HIV-related deaths based on the InterVA algorithm.

As a final limitation, we note that our estimates of HIV-cause-deleted life expectancy are interpretable as counterfactual life expectancy in a world without HIV mortality only if HIV and non-HIV causes of death are indeed independent. Although we cannot test this formally (individuals can die only once), we find supporting evidence from several sources. The near-normal life expectancy of patients on ART in previous studies suggests that HIV patients do not face substantially higher or lower mortality rates due to other causes than the general population. The stability of our observed trends in HIV-cause-deleted life expectancy during a period of rapidly falling HIV mortality is also consistent with such an interpretation. Finally, in sensitivity analyses, we found that even very large violations of the independence assumption would not substantially affect our inferences about HIV-cause-deleted life expectancy. Though we cannot rule out dependence across causes, our estimates of HIV-cause-deleted life expectancy likely provide a reasonable estimate of the potential adult life expectancy that would be observed with the elimination of HIV mortality, e.g., through further advances in treatment and prevention (see S1 Text for further discussion of these points).

This paper offers a population perspective on the gendered impacts of mass HIV treatment [12,16,48,49]. Though population adult life expectancy has increased dramatically for women during the scale-up of ART, the gains for men have been more modest. This difference is partially explained by the fact that women had a larger number of years of life lost due to HIV than men prior to treatment scale-up; ART has led to a “natural” decompression in the female–male life expectancy gap as HIV mortality has declined. Yet this is not the whole story. HIV mortality has declined significantly faster among women than among men, and male sex has emerged as a risk factor for HIV mortality in this setting. A high proportion of HIV-related deaths occurred among men who had never sought care or treatment for HIV in the public sector, despite the fact that treatment is widely available and free at point of service. Gender-targeted programming has often sought to improve health for women and girls. Our results suggest that further research to understand male deficits in care-seeking and to design effective interventions to increase uptake of HIV services among men is needed to realize the full benefits of mass ART provision. Without better outreach to men, achievement of the Joint United Nations Programme on HIV/AIDS 2020 targets of 90% tested, 90% initiated, and 90% virally suppressed [50] is unlikely. Additionally, given the prevention benefits of ART, male-sensitive programming may be necessary to reduce the burden of HIV disease among men and women alike.

Supporting Information

Attachment 1

Attachment 2

Attachment 3

Attachment 4

Attachment 5

Attachment 6

Attachment 7

Attachment 8

Attachment 9

Attachment 10

Attachment 11


Zdroje

1. Bor J, Herbst A, Newell M, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339:961–965. doi: 10.1126/science.1230413 23430655

2. Reniers G, Eaton J, Nakiyingi-Miiro J, Crampin A, Kabudula C, Herbst K, et al. The impact of antiretroviral therapy on adult life expectancy in sub-Saharan Africa [abstract]. Conference on Retroviruses and Opportunistic Infections (CROI 2015); 23–26 Feb 2015; Seattle, WA, US.

3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0 23245604

4. Pillay Y. Operational and programmatic considerations in scaling up ART [abstract]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun–3 Jul 2013; Kuala Lumpur, Malaysia.

5. World Health Organization. World health statistics 2012. Geneva: World Health Organization; 2012.

6. Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Zungu N, et al. South African national HIV prevalence, incidence and behaviour survey, 2012. Cape Town: Human Sciences Research Council; 2014.

7. Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012;17:1509–1520. doi: 10.1111/j.1365-3156.2012.03089.x 22994151

8. Bärnighausen T, Tanser F, Herbst K, Mutevedzi T, Mossong J, Newell M. Structural barriers to antiretroviral treatment: a study using population-based CD4 cell count and linked antiretroviral treatment programme data [abstract]. Lancet. 2013;382(S5):3935. doi: 10.1016/S0140-6736(13)62253-9

9. Bassett I, Regan S, Luthuli P, Mbonambi H, Bearnot B, Pendleton A, et al. Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South Africa. HIV Med. 2014;15:367–372. doi: 10.1111/hiv.12115 24251725

10. Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56:e79. doi: 10.1097/QAI.0b013e3182075ae2 21157360

11. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS. 2011;25:1189–1197. doi: 10.1097/QAD.0b013e3283471deb 21505309

12. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 2012;9:e1001304. doi: 10.1371/journal.pmed.1001304 22973181

13. Lahuerta M, Wu Y, Hoffman S, Elul B, Kulkarni SG, Remien RH, et al. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006–2011: findings from four sub-saharan African countries. Clin Infect Dis. 2014;58:432–441. doi: 10.1093/cid/cit724 24198226

14. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, et al. Treatment interruption in a primary care antiretroviral therapy programme in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55:e17–e23. doi: 10.1097/QAI.0b013e3181f275fd 20827216

15. Mills EJ, Bakanda C, Birungi J, Chan K, Hogg RS, Ford N, et al. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc. 2011;14:52. doi: 10.1186/1758-2652-14-52 22050673

16. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS. 2013;27:417–425. doi: 10.1097/QAD.0b013e328359b89b 22948271

17. Maskew M, Brennan AT, Westreich D, McNamara L, MacPhail AP, Fox MP. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt). 2013;22:113–120. doi: 10.1089/jwh.2012.3585

18. Zaidi J, Grapsa E, Tanser F, Newell M-L, Bärnighausen T. Dramatic increase in HIV prevalence after scale-up of antiretroviral treatment. AIDS. 2013;27:2301–2305. doi: 10.1097/QAD.0b013e328362e832 23669155

19. Bor J, Bärnighausen T, Newell C, Tanser F, Newell ML. Social exposure to an antiretroviral treatment programme in rural KwaZulu‐Natal. Trop Med Int Health. 2011;16:988–994. doi: 10.1111/j.1365-3156.2011.02795.x 21615631

20. Bor J, Tanser F, Newell M-L, Bärnighausen T. In a study of a population cohort in South Africa, HIV patients on antiretrovirals had nearly full recovery of employment. Health Aff (Millwood). 2012;31:1459–1469. doi: 10.1377/hlthaff.2012.0407

21. Tanser F, Hosegood V, Bärnighausen T, Herbst K, Nyirenda M, Muhwava W, et al. Cohort profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol. 2008;37:956–962. doi: 10.1093/ije/dym211 17998242

22. Herbst AJ, Mafojane T, Newell M-L. Verbal autopsy-based cause-specific mortality trends in rural KwaZulu-Natal, South Africa, 2000–2009. Popul Health Metr. 2011;9:47. doi: 10.1186/1478-7954-9-47 21819602

23. Herbst AJ, Cooke GS, Bärnighausen T, KanyKany A, Tanser F, Newell M-L. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ. 2009;87:754–762. 19876542

24. Byass P, Calvert C, Miiro-Nakiyingi J, Lutalo T, Michael D, Crampin A, et al. InterVA-4 as a public health tool for measuring HIV/AIDS mortality: a validation study from five African countries. Glob Health Action. 2013;6:22448. doi: 10.3402/gha.v6i0.22448 24138838

25. Byass P, Herbst K, Fottrell E, Ali MM, Odhiambo F, Amek N, et al. Comparing verbal autopsy cause of death findings as determined by physician coding and probabilistic modelling: a public health analysis of 54 000 deaths in Africa and Asia. J Glob Health. 2015;5:010402. doi: 10.7189/jogh.05.010402 25734004

26. Bärnighausen T, Bor J, Wandira-Kazibwe S, Canning D. Correcting HIV prevalence estimates for survey nonparticipation using Heckman-type selection models. Epidemiology. 2011;22:27–35. doi: 10.1097/EDE.0b013e3181ffa201 21150352

27. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209–217. doi: 10.7326/0003-4819-155-4-201108160-00358 21768555

28. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418. doi: 10.1371/journal.pmed.1001418 23585736

29. Welaga P, Hosegood V, Weiner R, Hill C, Herbst K, Newell M-L. Coming home to die? the association between migration and mortality in rural South Africa. BMC Public Health. 2009;9:193. doi: 10.1186/1471-2458-9-193 19538717

30. Garrib A, Herbst AJ, Hosegood V, Newell M-L. Injury mortality in rural South Africa 2000–2007: rates and associated factors. Trop Med Int Health. 2011;16:439–446. doi: 10.1111/j.1365-3156.2011.02730.x 21284789

31. Schneider H, Govender V, Harris B, Cleary S, Moshabela M, Birch S. Gender differences in experiences of ART services in South Africa: a mixed methods study. Trop Med Int Health. 2012;17:820–826. doi: 10.1111/j.1365-3156.2012.03009.x 22594691

32. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005;49:616–623. doi: 10.1111/j.1365-2648.2004.03331.x 15737222

33. Goga AE, Dinh T-H, Jackson DJ, Lombard C, Delaney KP, Puren A, et al. First population-level effectiveness evaluation of a national programme to prevent HIV transmission from mother to child, South Africa. J Epidemiol Community Health. 2014;69:240–248. doi: 10.1136/jech-2014-204535 25371480

34. Madiba S, Canti-Sigaqa V. Barriers to participate in support groups for people living with HIV: A qualitative study with men receiving antiretroviral treatment in a HIV clinic in Mthatha, South Africa. Glob J Health Sci. 2012;4:119–128. doi: 10.5539/gjhs.v4n6p119 23121748

35. Camlin CS, Hosegood V, Newell M-L, McGrath N, Bärnighausen T, Snow RC. Gender, migration and HIV in rural KwaZulu-Natal, South Africa. PLoS ONE. 2010;5:e11539. doi: 10.1371/journal.pone.0011539 20634965

36. Bor J, Moscoe E, Mutevedzi P, Newell M-L, Bärnighausen T. Regression discontinuity designs in epidemiology: causal inference without randomized trials. Epidemiology. 2014;25:729–737. doi: 10.1097/EDE.0000000000000138 25061922

37. Thirumurthy H, Zivin JG, Goldstein M. The economic impact of AIDS treatment: labor supply in western Kenya. J Hum Resour. 2008;43:511–552. 22180664

38. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, Shaffer D, et al. Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health. 2009;9:240. doi: 10.1186/1471-2458-9-240 19604381

39. Zivin JG, Thirumurthy H, Goldstein M. AIDS treatment and intrahousehold resource allocation: children’s nutrition and schooling in Kenya. J Public Econ. 2009;93:1008–1015. 22180689

40. Bor J, Tanser F, Newell M-L, Bärnighausen T. Economic spillover effects of ART on rural South African households [abstract]. International AIDS and Economics Network 7th AIDS and Economics Pre-Conference; 20–21 Jul 2012; Washington, DC, US.

41. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. doi: 10.1056/NEJMoa1105243 21767103

42. Chimbindi N, Bor J, Newell ML, Tanser F, Baltussen R, Hontelez J, et al. Time and money: the true costs of health care utilization for patients receiving “free” HIV/tuberculosis care and treatment in rural KwaZulu-Natal. JAIDS. 2015;70(2):e52–e60.

43. Wilson N. Antiretroviral therapy and demand for HIV testing: evidence from Zambia. 1 August 2011. Social Science Research Network. doi: 10.2139/ssrn.1982185

44. Lozano R, Freeman MK, James SL, Campbell B, Lopez AD, Flaxman AD, et al. Performance of InterVA for assigning causes of death to verbal autopsies: multisite validation study using clinical diagnostic gold standards. Popul Health Metr. 2011;9:50. doi: 10.1186/1478-7954-9-50 21819580

45. Murray CJL, Lozano R, Flaxman AD, Serina P, Phillips D, Stewart A, et al. Using verbal autopsy to measure causes of death: the comparative performance of existing methods. BMC Med. 2014;12:5. doi: 10.1186/1741-7015-12-5 24405531

46. Hosegood V, Vanneste A-M, Timaeus IM. Levels and causes of adult mortality in rural South Africa: the impact of AIDS. AIDS. 2004;18:663–671. doi: 10.1097/01.aids.0000111463.61782.aa 15090772

47. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis. 2011;15:571–581. doi: 10.5588/ijtld.10.0483 21756508

48. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our blind spot. Trop Med Int Health. 2011;16:828–829. doi: 10.1111/j.1365-3156.2011.02767.x 21418449

49. Cornell M, Myer L. Men and mortality: sex inequality in health outcomes. AIDS. 2013;27:849–850. doi: 10.1097/QAD.0b013e32835e399b 23719356

50. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2014. Available: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed 20 October 2015.

Štítky
Interní lékařství

Článek vyšel v časopise

PLOS Medicine


2015 Číslo 11

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Diabetická neuropatie a její léčba
nový kurz
Autoři: MUDr. Michal Dubský, Ph.D.

Mnohočetný myelom: Úvodní léčba netransplantovatelných pacientů
Autoři:

Proč v prevenci zubního kazu kartáček nestačí?
Autoři: doc. MUDr. Romana Koberová – Ivančaková, CSc.

Hypersenzitivita dentinu jako příznak poškození tvrdých zubních tkání
Autoři: MUDr. Erika Lenčová, Ph.D.

Cesta pacienta s CHOPN
Autoři: doc. MUDr. Vladimír Koblížek, Ph.D.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se